ArticleBMC gastroenterology2025
Management and outcomes of patients with obstructive jaundice from pancreatobiliary diseases in Rwanda.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Reduction of serum bilirubin levels after endoscopic biliary drainage in patients with extrahepatic biliary obstruction and its significance.World journal of gastrointestinal endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive jaundice from pancreatobiliary diseases represents a significant global health challenge, particularly in resource-limited settings like Rwanda. While endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD) are now available at tertiary centers in Kigali, there is limited local clinical data on the management and outcomes of these conditions. This study aims to assess the patterns, therapeutic approaches, and outcomes of obstructive jaundice in the Rwandan healthcare context.
methodsA cross-sectional study was conducted across three tertiary hospitals (KFH, RMH, and CHUK) in Rwanda from July 2023 to June 2024. Using Fischer's formula, 158 patients with obstructive jaundice from pancreatobiliary diseases were enrolled. Data collection involved chart reviews at admission, procedure, post-procedure, discharge, and 30-day follow-up. Analysis was performed using Stata version 13, with descriptive statistics, bivariate analysis using chi-square, and multivariate analyses examining predictors of 30-days mortality among the participants at 95% confidence interval and p value < 0.05 considered statistically significant. Multicollinearity assessment was also performed considering the target variance inflation factor (VIF) < 5.
resultsIn this study of 158 patients with obstructive jaundice in Rwanda, ERCP was the predominant intervention (77.54%), followed by PTBD (17.39%) and surgical procedures (5.07%). The overall procedures technical success rate was 82.61%; with PTBD success rate of 91.67%, surgical procedures showed higher success rate 100%, while ERCP had a success rate of 79.44%. Post-procedure complications occurred in 16.67% of cases, including pancreatitis (5%), bleeding (3.62%), and mortality (4.34%). The 30-day survival rate was 92.41%, demonstrating generally favorable outcomes in managing pancreaticobiliary diseases. The multivariate analysis showed that weight loss increased mortality risk (aOR = 10.647, 95% CI: 1.190-95.256, p = 0.034), while the absence of CBD stones was protective (aOR = 0.087, 95% CI: 0.008-0.888, p = 0.039). Having a procedure performed significantly reduced mortality odds (aOR = 0.025, 95% CI: 0.006-0.117, p < 0.001). ICU/HDU admission was associated with higher mortality risk in 30 days (aOR = 13.051, 95% CI: 2.010-84.731, p = 0.007).
conclusionThis study from Rwanda provides crucial insights into the management and outcomes of obstructive jaundice from pancreatobiliary diseases. PTBD was demonstrated high success. While post-procedure complications occurred, the 30-day survival rate was favorable. Weight loss and ICU admission were associated with increased mortality, while procedural interventions showed protective effects, highlighting the importance of timely management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.